John V. Heymach, MD, PhD
Poziotinib (NOV120101, HM781-36B) demonstrated high antitumor activity in patients with metastatic, heavily pretreated EGFR
exon 20 mutant non–small cell lung cancer (NSCLC), according to phase II study results presented at the 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada.1
-related toxicities—including rash, diarrhea, and paronychia—were substantial but manageable,” Heymach noted.
Heymach J, Negrao M, Robichaux J, et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). Presented at: The IASLC 19th World Conference on Lung Cancer; September 23-26, 2018; Toronto, Canada. Abstract OA02.06.
... to read the full story